Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.2M | $12.3M | $17.4M | $23.2M | $24.2M | $23.5M | $27.9M | $28.5M | $33.6M | $41.1M |
| Revenue growth | — | 0.4% | 41.2% | 33.5% | 4.4% | -2.8% | 18.8% | 2.2% | 18.0% | 22.2% |
| Gross profit | $7.60M | $7.57M | $10.8M | $14.9M | $14.9M | $13.8M | $15.4M | $16.7M | $21.3M | $25.6M |
| Gross margin | 62.1% | 61.6% | 62.3% | 64.1% | 61.8% | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Operating income | $1.18M | -$736K | $1.16M | $586K | -$1.25M | -$7.03M | -$10.8M | -$10.3M | -$6.45M | -$2.97M |
| Operating margin | 9.6% | -6.0% | 6.7% | 2.5% | -5.2% | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Net income | $783K | -$535K | $911K | $564K | -$1.21M | -$4.56M | -$8.66M | -$13.7M | -$6.07M | -$2.64M |
| Net margin | 6.4% | -4.4% | 5.2% | 2.4% | -5.0% | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (diluted) | $0.02 | -$0.01 | $0.02 | $0.01 | -$0.03 | -$0.10 | -$0.19 | -$0.30 | -$0.13 | -$0.06 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.91M | -$332K | $1.48M | $321K | -$743K | -$4.32M | -$5.40M | -$4.89M | -$320K | $462K |
| Capital expenditures | $122K | $203K | $297K | $201K | $921K | $346K | $2.76M | $783K | $1.30M | $933K |
| Free cash flow | $1.79M | -$535K | $1.18M | $119K | -$1.66M | -$4.67M | -$8.17M | -$5.68M | -$1.62M | -$470K |
| Share buybacks | — | — | — | $2.82K | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.20M | $3.97M | $3.74M | $5.87M | $27.3M | $25.3M | $17.4M | $11.5M | $9.58M | $8.87M |
| Total assets | $8.39M | $9.28M | $10.5M | $13.9M | $39.9M | $41.3M | $42.3M | $28.5M | $27.2M | $28.2M |
| Total liabilities | $1.28M | $1.61M | $1.58M | $2.65M | $3.76M | $4.79M | $11.0M | $8.11M | $10.4M | $11.2M |
| Shareholders' equity | $7.12M | $7.67M | $8.96M | $11.2M | $36.2M | $36.5M | $31.3M | $20.4M | $16.8M | $17.0M |
| Retained earnings | $3.02M | $3.39M | $4.30M | $4.86M | $3.65M | -$910K | -$9.57M | -$23.3M | -$29.4M | -$32.0M |
| Shares (wtd avg diluted) | 38.0M | 37.9M | 38.9M | 39.1M | 41.9M | 44.4M | 45.0M | 45.6M | 45.8M | 46.2M |
Every figure is extracted from KORU Medical Systems, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.